BRPI0413028A - composto, uso de um composto, composição farmacêutica, e, kit farmacêutico - Google Patents

composto, uso de um composto, composição farmacêutica, e, kit farmacêutico

Info

Publication number
BRPI0413028A
BRPI0413028A BRPI0413028-6A BRPI0413028A BRPI0413028A BR PI0413028 A BRPI0413028 A BR PI0413028A BR PI0413028 A BRPI0413028 A BR PI0413028A BR PI0413028 A BRPI0413028 A BR PI0413028A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical
pharmaceutical composition
kit
pharmaceutical kit
Prior art date
Application number
BRPI0413028-6A
Other languages
English (en)
Inventor
Nicoletta Almirante
Piero Del Soldato
Ennio Ongini
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of BRPI0413028A publication Critical patent/BRPI0413028A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, KIT FARMACêUTICO". Nitro-derivados de bloqueador do receptor de Angiotensina II da fórmula (I): R-(Y-ONO~ 2~)~ s~ (I) tendo uma atividade farmacológica mais ampla e uma tolerância aumentada. Eles podem ser utilizados para o tratamento de doenças cardiovasculares, renais e crónicas do fígado e em processos inflamatórios.
BRPI0413028-6A 2003-07-31 2004-07-20 composto, uso de um composto, composição farmacêutica, e, kit farmacêutico BRPI0413028A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102379 2003-07-31
PCT/EP2004/051550 WO2005011646A2 (en) 2003-07-31 2004-07-20 Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
BRPI0413028A true BRPI0413028A (pt) 2006-10-03

Family

ID=34112476

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413028-6A BRPI0413028A (pt) 2003-07-31 2004-07-20 composto, uso de um composto, composição farmacêutica, e, kit farmacêutico

Country Status (29)

Country Link
US (1) US20060276523A1 (pt)
EP (1) EP1653950B1 (pt)
JP (1) JP2007500684A (pt)
KR (1) KR20060056352A (pt)
CN (1) CN100496490C (pt)
AR (1) AR045145A1 (pt)
AT (1) ATE383155T1 (pt)
AU (1) AU2004260830B2 (pt)
BR (1) BRPI0413028A (pt)
CA (1) CA2534451A1 (pt)
CY (1) CY1110447T1 (pt)
DE (1) DE602004011230T2 (pt)
DK (1) DK1653950T3 (pt)
EC (1) ECSP066334A (pt)
ES (1) ES2299861T3 (pt)
HR (1) HRP20060084A2 (pt)
IL (1) IL172703A0 (pt)
IS (1) IS2534B (pt)
MA (1) MA27987A1 (pt)
MX (1) MXPA06001263A (pt)
NO (1) NO20060900L (pt)
NZ (1) NZ544463A (pt)
PL (2) PL379420A1 (pt)
PT (1) PT1653950E (pt)
RU (1) RU2374240C2 (pt)
SI (1) SI1653950T1 (pt)
UA (1) UA87983C2 (pt)
WO (1) WO2005011646A2 (pt)
ZA (1) ZA200600856B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723529B2 (en) 2004-07-20 2010-05-25 Nicox S.A. Process for preparing nitrooxy esters, nitrooxy thioesters nitrooxy carbonates and nitrooxy thiocarbinates, intermediates useful in said process and preparation thereof
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
RU2306930C1 (ru) * 2005-12-28 2007-09-27 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции комбинацией лозартана и l-аргинина при l-name-индуцированном дефиците оксида азота
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
JP5290190B2 (ja) * 2006-12-06 2013-09-18 サルブリス・アセット・マネイジメント・カンパニー・リミテッド イミダゾール−５−カルボン酸誘導体の塩、製造方法及びその医薬組成物
JP2010513273A (ja) * 2006-12-13 2010-04-30 メルク アンド カンパニー インク． アンジオテンシンｉｉ受容体拮抗薬
TW200831079A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
EP1980559A1 (en) * 2007-04-10 2008-10-15 CTG Pharma S.r.l. Cardiovascular agents
CN101317842A (zh) 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) * 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
AR069340A1 (es) 2007-11-26 2010-01-13 Merck & Co Inc Antagonistas del receptor de angiotensina ii
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
WO2009094242A1 (en) * 2008-01-24 2009-07-30 Merck & Co., Inc. Angiotensin ii receptor antagonists
AU2009210484A1 (en) 2008-02-08 2009-08-13 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
CA2712689A1 (en) * 2008-02-26 2009-09-03 Nicoletta Almirante Angiotensin ii receptor antagonists
CA2712695A1 (en) * 2008-02-26 2009-09-03 Nicoletta Almirante New angiotensin ii receptor blocker derivatives
US8207208B2 (en) * 2008-05-15 2012-06-26 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
WO2009150007A1 (en) * 2008-06-09 2009-12-17 Nicox S.A. Angiotensin ii receptor antagonists
AR073259A1 (es) * 2008-07-29 2010-10-28 Merck & Co Inc Derivados de furosemida utiles como diureticos
WO2010015447A1 (en) * 2008-08-08 2010-02-11 Nicox S.A. Angiotensin ii receptor antagonists
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
CA2745095A1 (en) * 2008-12-05 2010-06-10 Merck Sharp & Dohme Corp. Nitrooxy derivatives as angiotensin ii receptor antagonists
MA33056B1 (fr) 2009-01-23 2012-02-01 Hanmi Holding Co Ltd Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
WO2011131613A1 (en) 2010-04-19 2011-10-27 Cardiolynx Ag Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
EP2560634A1 (en) * 2010-04-23 2013-02-27 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
WO2011160974A2 (en) 2010-06-21 2011-12-29 Nicox S.A. Statin derivatives
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
CA2897571C (en) 2013-01-21 2018-12-18 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group
CN103275074B (zh) * 2013-06-21 2016-08-10 黄冈鲁班药业股份有限公司 一种奥美沙坦衍生物及其制备方法
CN105820125B (zh) * 2015-01-09 2018-12-07 北京中医药大学 一种用于治疗高血压的化合物及其制备方法和用途
JP2018526448A (ja) 2015-09-07 2018-09-13 浙江華海薬業股▲フン▼有限公司 一酸化窒素を放出可能なプロドラッグ分子
CN106800537B (zh) 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN108892624B (zh) * 2018-06-20 2020-12-15 重庆威鹏药业有限公司 沙库巴曲硝基氧衍生物及其制备方法和应用
CN114105881B (zh) * 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
DK0403159T3 (da) * 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
SG52709A1 (en) * 1989-06-30 1998-09-28 Du Pont Substituted imidazoles
RU2067581C1 (ru) * 1989-06-30 1996-10-10 Е.И.Дюпон Де Немур Энд Компани Аралкилзамещенные имидазолы, обладающие противогипертоническим действием, способ их получения и фармацевтический состав, обладающий ингибирующей активностью в отношении ангиотензина ii
AT398202B (de) * 1991-10-04 1994-10-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
ITMI20011744A1 (it) * 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie

Also Published As

Publication number Publication date
DE602004011230T2 (de) 2009-01-02
CA2534451A1 (en) 2005-02-10
ZA200600856B (en) 2007-05-30
ES2299861T3 (es) 2008-06-01
WO2005011646A2 (en) 2005-02-10
CY1110447T1 (el) 2015-04-29
PL379420A1 (pl) 2006-09-04
MA27987A1 (fr) 2006-07-03
IS2534B (is) 2009-08-15
CN100496490C (zh) 2009-06-10
IL172703A0 (en) 2006-04-10
KR20060056352A (ko) 2006-05-24
SI1653950T1 (sl) 2008-06-30
DE602004011230D1 (de) 2008-02-21
EP1653950A2 (en) 2006-05-10
AR045145A1 (es) 2005-10-19
HRP20060084A2 (hr) 2006-04-30
ECSP066334A (es) 2006-07-28
MXPA06001263A (es) 2006-04-11
UA87983C2 (ru) 2009-09-10
CN1832742A (zh) 2006-09-13
PL1653950T3 (pl) 2008-08-29
HK1095093A1 (zh) 2007-04-27
US20060276523A1 (en) 2006-12-07
NZ544463A (en) 2009-10-30
JP2007500684A (ja) 2007-01-18
WO2005011646A3 (en) 2005-04-21
EP1653950B1 (en) 2008-01-09
NO20060900L (no) 2006-02-24
RU2374240C2 (ru) 2009-11-27
IS8332A (is) 2006-02-27
DK1653950T3 (da) 2008-05-26
AU2004260830A1 (en) 2005-02-10
AU2004260830B2 (en) 2010-04-29
RU2006105804A (ru) 2007-09-20
PT1653950E (pt) 2008-04-11
ATE383155T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
BRPI0413028A (pt) composto, uso de um composto, composição farmacêutica, e, kit farmacêutico
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
ECSP055525A (es) Inhibidores de cinasas de tirosina
DE60130256D1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
BRPI0414539A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
BR9910864A (pt) Compostos anti-inflamatórios para inibição de aderência celular
BR0111034A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
ATE381333T1 (de) Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
ATE383859T1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
ATE430135T1 (de) Benzimidazolderivate, zusammensetzungen, die diese enthalten, zubereitung davon und deren verwendungen
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
BR0008468A (pt) Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos
ATE485049T1 (de) Physiologisch aktive zusammensetzung gegen diabetes
SG152257A1 (en) Topical preparation containing ambroxol
PT1492773E (pt) Compostos de 4-(heterociclilo)-benzenossulfoximinapara o tratamento da inflamação
HRP20050439B1 (hr) Nova upotreba dekstran sulfata
PT1165065E (pt) Comprimidos para degluticao com elevada concentracao de n-acetilcisteina
ATE356143T1 (de) Antibiotikum 107891, dessen faktoren a1 und a2, pharmazeutisch unbedenkliche salze und zusammensetzungen, und anwendung davon
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.